These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 9220293)

  • 21. A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers.
    Ardalan B; Singh G; Silberman H
    J Clin Oncol; 1988 Jun; 6(6):1053-8. PubMed ID: 3373260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. N-(phosphonacetyl)-L-aspartate and calcium leucovorin modulation of fluorouracil administered by constant rate and circadian pattern of infusion over 72 hours in metastatic gastrointestinal adenocarcinoma.
    Grem JL; Yee LK; Schuler B; Hamilton JM; Chen AP; Chabuk C; Grollman F; Grabenc M; Allegra CJ; Takimoto CH
    Ann Oncol; 2001 Nov; 12(11):1581-7. PubMed ID: 11822758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II trial of biochemical modulation using N-phosphonacetyl-L-aspartate, high-dose methotrexate, high-dose 5-fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site.
    Kelsen D; Martin DS; Colofiore J; Sawyer R; Coit D
    Cancer; 1992 Oct; 70(7):1988-92. PubMed ID: 1381991
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study.
    Whitehead RP; Benedetti JK; Abbruzzese JL; Ardalan B; Williamson S; Gaynor ER; Balcerzak SP; Macdonald JS
    Invest New Drugs; 2004 Nov; 22(4):467-73. PubMed ID: 15292717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma.
    Cao S; Rustum YM; Spector T
    Cancer Res; 1994 Mar; 54(6):1507-10. PubMed ID: 8137256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas.
    Ardalan B; Ucar A; Reddy R; Livingstone AS; Markoe A; Schwade J; Richman SP; Donofrio K
    Cancer; 1994 Oct; 74(7):1869-73. PubMed ID: 8082092
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The dead end of 5-fluorouracil double modulation and promise of continuous infusion schedules in the treatment of metastatic colorectal cancer.
    Köhne CH; Wilke H; Schöffski P; Schmoll HJ
    J Infus Chemother; 1996; 6(4):206-10. PubMed ID: 9229317
    [No Abstract]   [Full Text] [Related]  

  • 28. Preclinical and clinical aspects of biomodulation of 5-fluorouracil.
    Sotos GA; Grogan L; Allegra CJ
    Cancer Treat Rev; 1994 Jan; 20(1):11-49. PubMed ID: 7507404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of N-phosphonacetyl-L-aspartate, recombinant interferon-alpha, and fluorouracil infusion in advanced squamous cell carcinoma of the head and neck.
    Langer CJ; Schaebler D; Sauter E; DeMaria D; Johnson C; Reilly DM; Clark J; Leighton J; Aks C; Litwin S; Ridge JA
    Head Neck; 1998 Aug; 20(5):385-91. PubMed ID: 9663665
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group Study.
    Whitehead RP; Benedetti JK; Abbruzzese JL; Ardalan B; Goodwin JW; Balcerzak SP; Samlowski WE; Lenz HJ; Macdonald JS
    Invest New Drugs; 2004 Aug; 22(3):335-41. PubMed ID: 15122082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of PALA on the pharmacokinetics of 5-fluorouracil.
    Nassim MA; Rouini MR; Cripps MC; Shirazi FH; Veerasinghan S; Molepo JM; Obrocea M; Redmond D; Bates S; Fry D; Stewart DJ; Goel R
    Oncol Rep; 1998; 5(1):217-21. PubMed ID: 9458325
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biochemical modulation of 5-fluorouracil by PALA.
    O'Dwyer PJ
    Cancer Invest; 1990; 8(2):261-2. PubMed ID: 2400945
    [No Abstract]   [Full Text] [Related]  

  • 33. Phase I trial of N-(phosphonacetyl)-L-aspartate, methotrexate, and 5-fluorouracil with leucovorin rescue in patients with advanced cancer.
    Kemeny N; Schneider A; Martin DS; Colofiore J; Sawyer RC; Derby S; Salvia B
    Cancer Res; 1989 Aug; 49(16):4636-9. PubMed ID: 2472883
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD).
    Aranda E; Cervantes A; Carrato A; Antón-Torres A; Massutí T; Fernández-Martos C; Díaz-Rubio E
    J Infus Chemother; 1996; 6(3):118-22. PubMed ID: 9229321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II trial of low-dose N-(phosphonacetyl)-disodium L-aspartic acid and high-dose 24-hour infusional 5-fluorouracil in advanced gastric adenocarcinoma. A Southwest Oncology Group study.
    Martino RL; Fleming TR; Morrell LM; Ardalan B; Richman SP; Macdonald JS
    Invest New Drugs; 1996; 14(4):419-21. PubMed ID: 9157080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer. The Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD).
    Aranda E; Cervantes A; Dorta J; Blanco E; Fernández-Martos C; Cruz-Hernandez JJ; Carrato A; Gonzalez-Mancha R; García-Conde J; Díaz-Rubio E
    Cancer; 1995 Aug; 76(4):559-63. PubMed ID: 8625147
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer: a randomised phase II-III trial of the EORTC Gastrointestinal Group.
    Wils J; Blijham GH; Wagener T; De Greve J; Jansen RL; Kok TC; Nortier JW; Bleiberg H; Couvreur ML; Genicot B; Baron B;
    Eur J Cancer; 2003 Feb; 39(3):346-52. PubMed ID: 12565987
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients.
    Falcone A; Danesi R; Dargenio F; Pfanner E; Brunetti I; Del Tacca M; Nethersell AB; Conte PF
    J Clin Oncol; 1996 Mar; 14(3):729-36. PubMed ID: 8622018
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regional and systemic therapies for advanced colorectal carcinoma: randomized clinical trial results.
    Benson AB
    Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):28-34. PubMed ID: 9830622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
    Erlichman C; Donehower RC; Speyer JL; Klecker R; Chabner BA
    J Natl Cancer Inst; 1982 Feb; 68(2):227-31. PubMed ID: 6950156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.